InnoCare Receives Go-ahead for Clinical Trial of TYK2 Inhibitor ICP-332 in China
InnoCare, a biopharma firm developing novel therapies for the treatment of cancer and autoimmune diseases, today announced the approval of Phase I clinical trial of its novel TYK2 (Tyrosine Kinase 2) inhibitor, ICP-332, by the China National Medical Products Administration.
TYK2 (Tyrosine Kinase 2) inhibitor is a member of the JAK kinase family, which is an important kinase on the JAK-STAT signaling pathway, playing an important role in the pathogenesis of inflammatory diseases.
The company developed oral ICP-332, a potent and selective TYK2 inhibitor with 400 folds of sele...
